RT Journal Article
T1 Assessing the Impact of Nirsevimab Immunization on RSV Bronchiolitis Hospital Admissions and Their Severity: A Case‐Control Study and Comparison With Pre‐ and Post‐COVID‐19 Seasons in a Tertiary Pediatric Hospital
A1 Guerrero‐del‐Cueto, Fuensanta
A1 Lobato‐López, Sara
A1 Lozano‐Durán, Diego
A1 Sánchez‐Durán, Blanca
A1 Ramírez‐Martín, Lucía
A1 Esteban‐San‐Narciso, Begoña
A1 Sosa‐Hernández, Sara
A1 Martín‐Pedraz, Laura
A1 Moreno‐Pérez, David
A1 Leiva‐Gea, Isabel
A1 Núñez‐Cuadros, Esmeralda
K1 Bronquios - Enfermedades
K1 Epidemiología pediátrica - Andalucía
K1 COVID-19
AB Introduction: This study evaluates nirsevimab's real‐world effectiveness in preventing respiratory syncytial virus (RSV)bronchiolitis hospitalizations after its introduction in Andalusia's immunization schedule, compares clinical outcomes betweenimmunized and non‐immunized infants (2023–2024), and examines RSV seasonality pre‐ and post‐COVID‐19.Methods: Retrospective single‐center case‐control study conducted at a tertiary pediatric hospital (Malaga Regional UniversityHospital). Infants hospitalized for PCR‐confirmed RSV bronchiolitis during the first season after nirsevimab introduction werematched with two controls born on the same day. Immunization status, demographic data, and clinical outcomes wereanalyzed. As a secondary analysis, clinical characteristics and adverse outcomes of immunized and non‐immunized RSVbronchiolitis cases from the 2023–2024 season were compared with four previous periods: pre‐pandemic decade (04/2010–03/2020), first pandemic season (04/2020–03/2021), second pandemic season (04/2021–03/2022) and third pandemic season (04/2022–03/2023).Results: Nirsevimab showed 91.5% effectiveness (95% CI: 71.8%–97.4%) in reducing RSV bronchiolitis hospitalizations, whichdecreased 72.4% from the pre‐pandemic average and 82.4% from 04/2022–03/2023. Intensive‐care‐unit admissions were sig-nificantly higher in non‐immunized infants (60.0% vs. 26.1%, p = 0.04), with no differences in bacterial superinfection, oxygenrequirement and length‐of‐stay.Conclusions: Nirsevimab significantly reduced RSV bronchiolitis hospitalizations during its first season of use. The study alsohighlights shifts in RSV seasonality trends influenced by the COVID‐19 pandemic, highlighting the need for ongoing sur-veillance to adapt public health strategies.
PB Wiley
YR 2025
FD 2025
LK https://hdl.handle.net/10630/39530
UL https://hdl.handle.net/10630/39530
LA eng
NO Guerrero-Del-Cueto F, Lobato-Lopez S, Lozano-Duran D, Sanchez-Duran B, Ramirez-Martin L, Esteban-San-Narciso B, Sosa-Hernandez S, Martin-Pedraz L, Moreno-Perez D, Leiva-Gea I, Nuñez-Cuadros E. Assessing the Impact of Nirsevimab Immunization on RSV Bronchiolitis Hospital Admissions and Their Severity: A Case-Control Study and Comparison With Pre- and Post-COVID-19 Seasons in a Tertiary Pediatric Hospital. Pediatr Pulmonol. 2025 Jul;60(7):e71059. doi: 10.1002/ppul.71059. PMID: 40662491; PMCID: PMC12261432.
NO Funding for open access charge: Universidad de Málaga / CBUA
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 20 ene 2026